Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simnotrelvir + ritonavir + itraconazole
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Simnotrelvir (SIM0417, also known as SSD8432) is an oral small molecule inhibitor of the SARS-CoV-2 main protease (3CLpro), developed for the treatment of COVID-19. It acts by inhibiting viral replication through blockade of the 3-chymotrypsin-like protease essential for coronavirus maturation and propagation. Ritonavir is co-administered as a pharmacokinetic booster to inhibit CYP3A4-mediated metabolism and increase systemic exposure to simnotrelvir. Itraconazole is a triazole antifungal agent that strongly inhibits CYP3A4 and may further affect the pharmacokinetics of both simnotrelvir and ritonavir when used in combination. This triple combination has been studied in drug-drug interaction trials to evaluate safety and pharmacokinetic effects in healthy volunteers[1][2][5].
- Brand names
- XIANNUOXIN
- Other names
- SIM0417 + ritonavir + itraconazolesimnotrelvir/ritonavir/itraconazole
02
Targets
ABCB1 (P-glycoprotein)CYP3A4 (Cytochrome P450 3A4)Mpro (3C-like proteinase of SARS-CoV-2)
Beyond the preview
Go deeper on simnotrelvir + ritonavir + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simnotrelvir + ritonavir + itraconazole.